iBio Financials

$37 K

Revenue Q3, 2017

$16 M

Mkt cap, 20-Apr-2018
EBIT (Q3, 2017)(3.9 M)
Cash, 31-Mar-201712.4 M

Revenue/Financials

Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016

Revenue

205 k1.9 m948 k

Revenue growth, %

803%(49%)

R&D expense

1.9 m3.5 m3.2 m

General and administrative expense

3.9 m5 m7.7 m

Operating expense total

5.8 m8.5 m10.8 m

EBIT

(3.8 m)(6.7 m)(9.9 m)

EBIT margin, %

(1873%)(360%)(1044%)

Interest expense

807 k

Interest income

8 k9 k22 k

Net Income

(3.7 m)(6.6 m)(10.7 m)

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

819 k349 k160 k134 k379 k135 k75 k37 k

R&D expense

552 k585 k343 k1.2 m815 k551 k704 k1 m

General and administrative expense

949 k1.1 m951 k1.1 m1.2 m1.4 m1.7 m2.4 m2.5 m2.4 m2.8 m

Operating expense total

(240 k)1.6 m1.3 m2.2 m2 m2 m2.4 m3.5 m3.3 m3.4 m4 m

EBIT

240 k(1.6 m)(1.3 m)(1.4 m)(1.7 m)(1.8 m)(2.3 m)(3.1 m)(3.2 m)(3.3 m)(3.9 m)

EBIT margin, %

(173%)(484%)(1133%)(1682%)(811%)(2336%)(4433%)(10638%)

Interest expense

323 k483 k483 k481 k

Interest income

2 k2 k3 k1 k2 k2 k2 k5 k13 k12 k8 k

Net Income

379 k(1.6 m)(1.3 m)(1.4 m)(1.7 m)(1.8 m)(2.2 m)(3.6 m)

Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016

Cash

3.6 m9.5 m23 m

Inventories

118 k182 k264 k

Current Assets

3.9 m10.1 m23.9 m

PP&E

6 k13 k25.6 m

Total Assets

6.5 m12.5 m51.6 m

Accounts Payable

297 k1.1 m1.2 m

Current Liabilities

2.3 m

Total Liabilities

27.6 m

Additional Paid-in Capital

47.2 m59 m67.5 m

Retained Earnings

(41.2 m)(47.8 m)(57.6 m)

Total Equity

6.1 m11.2 m24 m

Financial Leverage

1.1 x1.1 x2.1 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

3.4 m5.7 m4.3 m3.5 m8.1 m8.4 m6.7 m21.9 m20.1 m16.3 m12.4 m

Current Assets

4.6 m6.9 m5.5 m4.1 m9 m9.1 m7.2 m22.7 m20.5 m16.7 m13 m

PP&E

5 k7 k20 k14 k10 k14 k25.8 m25.6 m25.5 m25.8 m

Total Assets

7.3 m9.6 m8.2 m6.7 m11.4 m11.4 m9.4 m50.7 m48.1 m44.2 m40.7 m

Accounts Payable

1.3 m1.2 m1.1 m516 k815 k1.3 m1.6 m979 k731 k1.4 m

Current Liabilities

1.2 m2.4 m2.2 m1.9 m2.6 m

Total Liabilities

1.7 m1.7 m1.2 m1.2 m1.3 m1.6 m1.5 m27.7 m27.4 m27 m27.8 m

Additional Paid-in Capital

42.8 m46.2 m47 m48 m56.1 m59.4 m59.7 m63.1 m67.7 m68 m80.7 m

Retained Earnings

(37.2 m)(38.8 m)(40.1 m)(42.6 m)(45.9 m)(49.6 m)(51.9 m)(54.9 m)(60.7 m)(63.9 m)(67.8 m)

Total Equity

7 m5.4 m10.2 m9.8 m7.9 m22.9 m20.7 m17.1 m12.9 m

Financial Leverage

1.2 x1.2 x1.1 x1.2 x1.2 x2.2 x2.3 x2.6 x3.1 x

Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016

Net Income

(3.7 m)(6.6 m)(10.7 m)

Depreciation and Amortization

361 k363 k940 k

Inventories

97 k(64 k)(82 k)

Accounts Payable

56 k806 k(125 k)

Cash From Operating Activities

(4.1 m)(4.7 m)(8.1 m)

Cash From Investing Activities

(259 k)(215 k)(68 k)

Cash From Financing Activities

3.6 m10.9 m21.7 m

Interest Paid

485 k

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

379 k(1.6 m)(1.3 m)(1.4 m)(1.7 m)(1.8 m)(4.1 m)(3.6 m)

Depreciation and Amortization

92 k184 k537 k412 k826 k1.3 m

Accounts Payable

1.1 m516 k815 k171 k190 k342 k53 k(255 k)7 k

Cash From Operating Activities

(1.1 m)(2.8 m)(5.3 m)(2.3 m)(5.8 m)(9.4 m)

Cash From Investing Activities

(18 k)(5 k)(8 k)(602 k)(765 k)(1.1 m)

Cash From Financing Activities

63 k63 k17.7 m(41 k)(83 k)(126 k)

Interest Paid

484 k966 k1.4 m

Ratios

USDY, 2017

Financial Leverage

3.1 x
Report incorrect company information

Operating Metrics

FY, 2016

Patents Issued

67

Patents Pending

19
Report incorrect company information